hotspot -WSS

hotspot

author：focus 2025-10-01 11:46:47 - browse：412

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Pfizer highlights cancer drugs it thinks could reignite investor interest

WSS

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Obesity now affects over 1 billion people worldwide, study finds

Ask STAT: What do you want to know about ChatGPT in medicine?

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Why drug prescriptions should include diagnoses

hotspot

hotspot

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ask STAT: What do you want to know about ChatGPT in medicine?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Pfizer highlights cancer drugs it thinks could reignite investor interest

After affirmative action ruling, medical educators look to 'holistic review'

Why drug prescriptions should include diagnoses

Drug repurposing or repositioning? The language matters

RaDonda Vaught to speak at CommonSpirit event on patient safety

Psychedelics group wrestles with new pharma identity

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

knowledge

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

The story of mRNA: From a loose idea to a tool that may help curb Covid

The science behind Janet Jackson's pregnancy at 49

Why getting cancer drugs just got harder for rural patients

Medical device lobby: We're tired of waiting on Medicare coverage

leisure time

Wikipedia

focus

hotspot